


PRODUCT INFORMATION



NVP-AUY922

Item No. 10012698

CAS Registry No.: 747412-49-3
Formal Name: 5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-3-isoxazolecarboxamide
Synonym: VER 52296
MF: C₂₆H₃₁N₃O₅
FW: 465.5
Purity: ≥98%
UV/Vis.: λ_{max}: 310 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NVP-AUY922 is supplied as a crystalline solid. A stock solution may be made by dissolving the NVP-AUY922 in the solvent of choice, which should be purged with an inert gas. NVP-AUY922 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of NVP-AUY922 in these solvents is approximately 14, 5, and 3 mg/ml, respectively.

NVP-AUY922 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NVP-AUY922 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. NVP-AUY922 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Hsp90 is a molecular chaperone of many different kinases, transcription factors, and hormone receptors involved in signal transduction, cell cycle regulation, and apoptosis. In addition to its important function in normal cell homeostasis, a high affinity form of Hsp90 is prevalent in tumor cells. Hsp90 inhibition has been associated with the degradation of oncogenic client proteins. NVP-AUY922 is a Hsp90 inhibitor (IC₅₀ = 21 nM in a FP binding assay) that prevents the proliferation of a range of human cancer cell lines *in vitro* with GI₅₀s averaging 9 nM.¹ In a human colon cancer xenograft model, 50 mg/kg NVP-AUY922 inhibits tumor growth by ~50% compared to vehicle controls.¹ Unlike some first generation Hsp90 inhibitors that are quickly glucuronidated, NVP-AUY922 is retained in tumors *in vivo* when administered at 4 mg/kg i.p. by cassette dosing in tumor-bearing mice.¹

Reference

1. Brough, P.A., Aherne, W., Barril, X., *et al.* 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. *J. Med. Chem.* **51**(2), 196-218 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM